RespireRx Pharmaceuticals Inc. Announces Participation SLEEP 2017 in Boston, MA
June 06 2017 - 5:00PM
Marketwired
RespireRx Pharmaceuticals Inc. Announces
Participation SLEEP 2017 in Boston, MA Senior Vice President of Research &
Development to Present Poster Session on a Phase 2A Clinical Trial
of CX1739 for the Prevention of Opioid Induced Respiratory
DepressionGLEN ROCK, NJ-(Marketwired - Jun 6, 2017) -
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in
the development of medicines for the treatment neurologically
controlled respiratory disorders for which there are no approved
pharmaceuticals, announces that the Company's Senior Vice President
of Research and Development, Richard Purcell will be presenting a
poster ("Poster") session entitled: "OPIOIDS AND SLEEP APNEA:
ANTAGONISM OF REMIFENTANIL INDUCED RESPIRATORY DEPRESSION BY CX1739
IN TWO CLINICAL MODELS OF OPIOID INDUCED RESPIRATORY DEPRESSION" at
the Sleep 2017 conference in Boston, MA on June 6, 2017 from 5:00 -
7:00pm EDT. "The focus of the Phase IIA clinical trial was
to advance the clinical proof of concept that CX1739, one of the
Company's low-impact Ampakines®, has clinical utility for the
treatment of respiratory depression resulting from high doses of
opioids for pain management," said Mr. Purcell. "This research
demonstrates not only the safety of the Ampakines, but also
target-engagement of CNS neurons that drive respiratory function",
he continued. "The data provide a clear clinical development path
for CX1739 for treating CNS-driven respiratory disorders like
central sleep apnea and spinal cord injury."
The contents of the Poster will be submitted to
the Securities and Exchange Commission in a Current Report on Form
8-K at the time of the presentation and will also be available in
the investors section of the RespireRx website.
SLEEP 2017 is the 31st Annual Meeting of the
Associated Professional Sleep Societies LLC ("APSS"), a joint
venture of the American Academy of Sleep
Medicine and the Sleep Research
Society. Among other things, the APSS provides
evidence-based education to advance the science and clinical
practice of sleep medicine, disseminates research results, and
promotes the translation of basic science into clinical
practice.In addition, a podium presentation describing
the results, previously announced by the Company, of a Phase 2B
study in which oral administration of dronabinol improved the
symptoms of obstructive sleep apnea will be made at the same
conference on June 6, 2017, from 1:45pm - 2:00pm
EDT.About RespireRx Pharmaceuticals
Inc. RespireRx Pharmaceuticals Inc. is a leader in
the development of medicines for neurologically controlled
respiratory disorders, with a focus on sleep apneas and
drug-induced respiratory depression. The Company owns patents and
patent applications, and holds exclusive licenses, for certain
families of chemical compounds that claim the chemical structures
and their use in the treatment of these and other disorders.
Pending additional funding, during 2017, the Company plans to: 1)
file an IND and initiate a Phase 2 clinical trial investigating the
ability of CX717 or CX1739 to improve breathing in patients with
spinal cord injury; 2) meet with the FDA to discuss its Phase 3
clinical trial program to test the safety and efficacy of
dronabinol (oral) for the treatment of Obstructive Sleep Apnea; and
3) file an IND and initiate a Phase 2 clinical trial investigating
the ability of CX1739 to reduce central sleep apnea in patients
taking chronic opioids.RespireRx's pharmaceutical candidates in
development are derived from two platforms, as described
below. One platform of medicines being developed by
RespireRx is a class of proprietary compounds known as ampakines
that act to enhance the actions of the excitatory neurotransmitter
glutamate at AMPA glutamate receptor sites in the brain. Several
ampakines in both oral and injectable form are being developed by
the Company for the treatment of a variety of breathing disorders,
one of which is the subject of the poster session described above.
Ampakines have also demonstrated that they may have utility to
improve breathing in animal models of disorders such as spinal cord
injury, Pompé Disease, and perinatal respiratory distress. The
Company's compounds belong to a new class of ampakines that do not
display the undesirable side effects previously reported for
earlier generations of ampakines.The other platform is the class of compounds
known as cannabinoids, including dronabinol. Under a license
agreement with the University of Illinois at Chicago, the Company
has rights to patents claiming the use of cannabinoids for the
treatment of sleep-related breathing disorders. The Phase 2B
clinical study, previously described by the Company in filings with
the SEC, is the subject of the podium presentation described
above.In an earlier placebo-controlled, dose-ascending
Phase 2A clinical study conducted by the Company, dronabinol
produced a statistically significant reduction in the AHI, the
primary therapeutic end-point, and was observed to be safe and
well-tolerated in a group of patients with OSA.
Additional information about the Company and the
matters discussed herein can be obtained on the Company's web-site
at www.RespireRx.com
or in the Company's filings with the U.S.
Securities and Exchange Commission on EDGAR at
www.sec.gov.Comments by the Company's President and Chief
Executive Officer Dr. James S. Manuso, commented, "We are pleased
to be represented at this prestigious medical meeting and to
continue informing the medical and research community of our
leading research and clinical development work in the areas of
apneas and other respiratory disorders, including
apneas/respiratory depression caused by opioids, obstructive sleep
apnea, disordered breathing associated with spinal cord injury and
other neurologically controlled breathing disorders. I look forward
to reporting to you our progress in the months
ahead." Special Note Regarding Forward-Looking
Statements: This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and the Company intends that such forward-looking
statements be subject to the safe harbor created thereby. Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions, both singular and plural, identify
forward-looking statements. Forward-looking statements include,
among other things, statements regarding future plans, targets,
estimates and assumptions. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by the Company, are inherently subject
to significant business, economic and competitive uncertainties and
contingencies. Many factors could cause the Company's actual
results to differ materially from those expressed or implied in any
forward-looking statements made by, or on behalf of, the Company.
Due to these various risks and uncertainties, actual events may
differ materially from current expectations. Investors are
cautioned that forward-looking statements are not guarantees of
future performance and, accordingly, investors are cautioned not to
put undue reliance on forward-looking statements due to the
inherent uncertainty therein. Forward-looking statements are made
as of the date of this news release and the Company disclaims any
intent or obligation to update publicly such forward-looking
statements, whether as a result of new information, future events
or results, or otherwise. Company Contact:Jeff MargolisVice-President,
Treasurer and SecretaryTelephone: (917)
834-7206E-mail: jmargolis@respirerx.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024